JP2015526487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526487A5 JP2015526487A5 JP2015528857A JP2015528857A JP2015526487A5 JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5 JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015528857 A JP2015528857 A JP 2015528857A JP 2015526487 A5 JP2015526487 A5 JP 2015526487A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- pharmaceutically acceptable
- mesomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210323870.3 | 2012-09-04 | ||
| CN201210323870 | 2012-09-04 | ||
| PCT/CN2013/082273 WO2014036897A1 (zh) | 2012-09-04 | 2013-08-26 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526487A JP2015526487A (ja) | 2015-09-10 |
| JP2015526487A5 true JP2015526487A5 (enExample) | 2017-12-21 |
| JP6262733B2 JP6262733B2 (ja) | 2018-01-17 |
Family
ID=50236528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528857A Active JP6262733B2 (ja) | 2012-09-04 | 2013-08-26 | イミダゾリン誘導体、その製造法、およびそれらの医薬への適用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9586947B2 (enExample) |
| EP (1) | EP2894151B1 (enExample) |
| JP (1) | JP6262733B2 (enExample) |
| KR (1) | KR102189940B1 (enExample) |
| CN (1) | CN103958480B (enExample) |
| AU (1) | AU2013312587B2 (enExample) |
| BR (1) | BR112015004637B1 (enExample) |
| CA (1) | CA2883545C (enExample) |
| CY (1) | CY1123649T1 (enExample) |
| DK (1) | DK2894151T3 (enExample) |
| ES (1) | ES2835248T3 (enExample) |
| HR (1) | HRP20202050T1 (enExample) |
| HU (1) | HUE052904T2 (enExample) |
| LT (1) | LT2894151T (enExample) |
| MX (1) | MX368844B (enExample) |
| PT (1) | PT2894151T (enExample) |
| RS (1) | RS61242B1 (enExample) |
| RU (1) | RU2639145C2 (enExample) |
| SI (1) | SI2894151T1 (enExample) |
| SM (1) | SMT202000672T1 (enExample) |
| TW (1) | TWI617546B (enExample) |
| WO (1) | WO2014036897A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2894151T1 (sl) * | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) * | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| DK3348546T3 (da) * | 2015-09-10 | 2020-07-06 | Jiangsu Hengrui Medicine Co | Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf |
| CN106518773A (zh) * | 2015-09-10 | 2017-03-22 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
| EP3417857B1 (en) * | 2016-02-19 | 2023-07-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition containing imidazoline derivative |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| WO2018009694A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| JP6773915B2 (ja) * | 2017-02-13 | 2020-10-21 | カング バイオファーマシューティカルズ リミテッド | 前立腺癌を治療する組み合わせ、薬物組成物および治療方法 |
| CN112174895B (zh) * | 2017-12-13 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
| CN110684046B (zh) * | 2018-07-06 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 一种新的咪唑啉类衍生物的制备方法 |
| CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| WO2020083187A1 (zh) * | 2018-10-22 | 2020-04-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 |
| BR112021011968A2 (pt) * | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
| AU2019404022A1 (en) * | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| GB201908511D0 (en) | 2019-06-13 | 2019-07-31 | Adorx Therapeutics Ltd | Hydroxamate compounds |
| CN113929628A (zh) * | 2020-06-29 | 2022-01-14 | 江苏恒瑞医药股份有限公司 | 一种咪唑啉衍生物的制备方法 |
| CN113024513A (zh) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | 新型雄激素受体降解剂、制备方法和医药用途 |
| CN117327019B (zh) * | 2022-06-23 | 2026-06-30 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂的应用 |
| CN115850186B (zh) * | 2023-02-07 | 2024-04-09 | 长沙泽达医药科技有限公司 | 一种乙撑硫脲衍生物的晶型及用途 |
| CN118993935B (zh) * | 2024-10-23 | 2025-02-14 | 江苏恒瑞医药股份有限公司 | 咪唑啉衍生物或其盐的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US7399775B2 (en) | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
| WO2004031160A2 (fr) * | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete |
| KR20070106969A (ko) | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
| US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| CN101817787B (zh) | 2009-02-26 | 2013-07-24 | 童友之 | 抗前列腺癌的雄性激素受体拮抗剂 |
| EP2416657A4 (en) * | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| WO2011008543A2 (en) | 2009-06-29 | 2011-01-20 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
| AU2011218167B2 (en) | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| CN103209960A (zh) | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| WO2012050868A1 (en) * | 2010-09-28 | 2012-04-19 | Georgia Tech Research Corporation | Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof |
| CN103619171B (zh) | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| WO2012119559A1 (en) * | 2011-03-10 | 2012-09-13 | Suzhou Kintor Pharmaceuticals,Inc. | Androgen receptor antagonists and uses thereof |
| SI2894151T1 (sl) * | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
-
2013
- 2013-08-26 SI SI201331826T patent/SI2894151T1/sl unknown
- 2013-08-26 US US14/425,207 patent/US9586947B2/en active Active
- 2013-08-26 AU AU2013312587A patent/AU2013312587B2/en active Active
- 2013-08-26 HU HUE13835193A patent/HUE052904T2/hu unknown
- 2013-08-26 WO PCT/CN2013/082273 patent/WO2014036897A1/zh not_active Ceased
- 2013-08-26 CN CN201380004069.5A patent/CN103958480B/zh active Active
- 2013-08-26 HR HRP20202050TT patent/HRP20202050T1/hr unknown
- 2013-08-26 RU RU2015110122A patent/RU2639145C2/ru active
- 2013-08-26 BR BR112015004637-1A patent/BR112015004637B1/pt active IP Right Grant
- 2013-08-26 EP EP13835193.7A patent/EP2894151B1/en active Active
- 2013-08-26 PT PT138351937T patent/PT2894151T/pt unknown
- 2013-08-26 DK DK13835193.7T patent/DK2894151T3/da active
- 2013-08-26 SM SM20200672T patent/SMT202000672T1/it unknown
- 2013-08-26 CA CA2883545A patent/CA2883545C/en active Active
- 2013-08-26 JP JP2015528857A patent/JP6262733B2/ja active Active
- 2013-08-26 ES ES13835193T patent/ES2835248T3/es active Active
- 2013-08-26 MX MX2015002602A patent/MX368844B/es active IP Right Grant
- 2013-08-26 LT LTEP13835193.7T patent/LT2894151T/lt unknown
- 2013-08-26 KR KR1020157007651A patent/KR102189940B1/ko active Active
- 2013-08-26 RS RS20201565A patent/RS61242B1/sr unknown
- 2013-08-30 TW TW102131223A patent/TWI617546B/zh active
-
2017
- 2017-01-20 US US15/411,517 patent/US9895355B2/en active Active
-
2020
- 2020-12-18 CY CY20201101202T patent/CY1123649T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015110122A (ru) | Производные имидазолина, способы их получения и их применение в медицине | |
| TWI674258B (zh) | Ｄｎａ烷化劑 | |
| JP2017533968A5 (enExample) | ||
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| JP2007509116A5 (enExample) | ||
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2013518106A5 (enExample) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2014185188A (ja) | フェニルおよびベンゾジオキシニル置換インダゾール誘導体 | |
| CA2727378A1 (en) | New co-crystal compound of rivaroxaban and malonic acid | |
| IL228072A (en) | Quinazoline compound is converted to alkyl and methods of use | |
| CN103804358A (zh) | 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 | |
| JP2018527328A (ja) | 置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法 | |
| JP2013521301A5 (enExample) | ||
| CA3050239A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| WO2014031755A1 (en) | Fendiline derivatives and methods of use thereof | |
| JP2019535825A5 (enExample) | ||
| AU2015367540B2 (en) | Substituted Pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| JP2017536342A5 (enExample) | ||
| WO2014164756A1 (en) | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use | |
| AU2022224918A1 (en) | Novel pyrazole derivatives | |
| RU2012126112A (ru) | Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения | |
| JP2009531363A5 (enExample) | ||
| JP5575357B2 (ja) | 組織因子産生抑制剤 |